Open AccessPOSSIBLE ROLE OF GENETIC POLYMORPHISMS FOR INDIVIDUALSENSITIVITY TO SIMVASTATIN IN INITIAL THERAPEUTIC DOSE
Author(s) -
Ksenia Zagorodnikova,
Ksenia Zagorodnikova,
А. А. Топанова,
А. А. Топанова,
M A Natas,
М А Настас,
В А Шумков,
В А Шумков
Publication year - 2015
Publication title -
vestnik severo-zapadnogo gosudarstvennogo medicinskogo universiteta im. i.i. mečnikova
Language(s) - English
Resource type - Journals
eISSN - 2618-9704
pISSN - 2618-7116
DOI - 10.17816/mechnikov20157153-57
Subject(s) - simvastatin , tolerability , pharmacology , cyp3a5 , adverse effect , medicine , therapeutic effect , hmg coa reductase , polymorphism (computer science) , genetic variants , genotype , bioinformatics , biology , gene , genetics , enzyme , biochemistry , reductase
Despite proven benefits of statins their effects and tolerability differ significantly in different patients. Genetic polymorphisms in genes of metabolizing enzymes, especially CYP3A5, and transporter proteins, especially OATP1B1, represent important factor for these changes. In our study we investigated influence of genetic polymorphisms on effects and safety of simvastatin 20 mg daily in 60 patients with dislipidemia. We observed reverse correlation of effects and adverse effects of simvastatin in our patients. Among CYP3A5*1 carriers we observed a tendency to less pronounced lipid-lowering effects (1,2 vs 2,9 mcmol/l). Our data may indicate importance of genetic polymorphisms even when statins are use in minimal therapeutic doses.